Classical swine fever virus marker vaccine strain CP7_E2alf: genetic stability in vitro and in vivo
Recently, CP7_E2alf (Suvaxyn®CSF Marker), a live marker vaccine against classical swine fever virus, was licensed through the European Medicines Agency. For application of such a genetically engineered virus under field conditions, knowledge about its genetic stability is essential. Here, we report on stability studies that were conducted to assess and compare the mutation rate of CP7_E2alf in vitro and in vivo. Sequence analyses upon passaging confirmed the high stability of CP7_E2alf, and no recombination events were observed in the experimental setup. The data obtained in this study confirm the genetic stability of CP7_E2alf as an important safety component.
Files
To see the attached files you have to login.
Cite
Citation style:
Could not load citation form.
Access Statistic

Rights
Use and reproduction:
All rights reserved